Today’s Solutions: November 30, 2021

Last week, Oregon voted to become the first state to legalize access to psilocybin for all adults. A new study reinforces the idea that voters made a sensible decision.

The preliminary human trials investigated the effect of psilocybin-assisted psychotherapy to treat the major depressive disorder (MDD). It is estimated that some 300 million people worldwide suffer from the debilitating condition. While a larger Phase 2 trial testing psilocybin for MDD is currently underway, this new study, in the journal JAMA Psychiatry, offers the first peer-reviewed published data showing efficacy for this particular mental health condition.

For the trials, a total of 24 subjects were recruited with at least two-years documented history of depression, with all subjects being required to wean off any anti-depressant treatment before the trial commenced. As reported in NewAtlas, depression was assessed using the standard GRID-Hamilton Depression Rating Scale. Severe depression scores 24 or higher on the scale, while seven or less is classified as no depression. At the beginning of the study, the average score for the cohort was 23.

The treatment process resembled the general protocol used in most psilocybin studies. Two doses of psilocybin were administered to each subject, spaced two weeks apart. A number of psychotherapy sessions both preceded and followed the active psilocybin sessions.

By the end of the study, 71 percent of the cohort displayed more than a 50 percent reduction in depressive symptoms after four weeks. A month later, the average depression score was done from 23 to 8, and more than half of the group were considered to be in remission. In comparison with studies focusing on the efficacy of antidepressants on MDD, psilocybin therapy was four times more effective.

Of course, the study itself isn’t without limitations. 24 subjects is a small sample size, and there was no placebo control. However, with a larger Phase 2 trial already underway, we can expect to get more accurate data on the therapeutic impact of psilocybin therapy relatively soon. 

Solutions News Source Print this article
More of Today's Solutions

Popcorn may be the next sustainable building material

Popcorn is more than just a tasty snack to munch on while at the movies—it may soon be widely used as a natural and eco-friendly alternative to man made home insulation. Scientists at Göttingen University ... Read More

Want to get students engaged? Consider career-based classes

Students who are engaged in the classroom are more likely to participate and retain more information, but what exactly keeps kids engaged? Researchers from Ohio State University surveyed 20,000 high school students across the US ... Read More

This 3D-printed eye is an eye-conic development for digital prosthetics

According to Moorfields Eye Hospital in London, Steve Verze, a 47-year-old engineer from Hackney, has been the fortunate recipient of the world’s first 3D printed eyeball. He first tried the eye on for size earlier ... Read More

Senegal’s only circus troupe helps homeless children get off the streets

Senegal has exactly one circus troupe: Sencirk—and it was founded by a former child beggar named Modou Touré. Before taking his place as ringmaster of his own circus, Touré, at the age of seven, was ... Read More

New breakthroughs in nutrient-sensing cells

Did you know immune cells can sense nutrients? A new study from St. Jude Children’s Research Hospital has identified the biological mechanism behind the phenomenon. The type of immune cells with these special abilities are ... Read More

How to stay warm this winter during outdoor social gatherings

Temperatures are dipping and snowflakes are falling, but that doesn’t mean we have to say goodbye to our outdoor social gatherings. Plus, it might not always be safe to gather indoors, and everyone will have ... Read More